Pharmacy World & Science

, Volume 30, Issue 1, pp 51–56 | Cite as

Medication use and disease management of type 2 diabetic flemish patients

  • Els MehuysEmail author
  • Leen De Bolle
  • Luc Van Bortel
  • Lieven Annemans
  • Inge Van Tongelen
  • Jean-Paul Remon
  • Mimi Giri
Research Article


Objective The aim of this study was (International Diabetes Federation. Diabetes Atlas Second Edition Executive Summary. Brussels: International Diabetes Federation; 2003) to describe the current status of medication use and disease management of type 2 diabetic patients in Flanders (Belgium), (World Health Organization. Prevention of diabetes mellitus. Technical report series no. 844. Geneva: World Health Organization; 1994) to identify the aspects of type 2 diabetes care a community pharmacist could provide additional educational services for, and (American Diabetes Association. Diabetes Care 2006;29:S4–42) to propose these services as a pharmacist intervention. Method We recruited 338 patients in 77 community pharmacies in Flanders (Belgium). Each patient completed a questionnaire collecting personal data, information on duration of diabetes, medication, diabetes symptoms and self-management. At inclusion, patients measured their fasting plasma glucose (FPG) on three consecutive days. Prescription drugs (antidiabetic and other) purchased by each patient during the 12 months prior to inclusion in the study were reviewed from anonymized computerized pharmacy records. Main outcome measures Degree of self-management, glycaemic control and medication use. Results The mean FPG of the sample was 150.7 ± 43.0 mg/dl. Controlled glycaemia (FPG between 90 and 130 mg/dl (5.0–7.2 mmol/l)) was achieved in only 34.9% of the patients. Mainstay of hypoglycemic treatment consisted of metformin monotherapy (29.6%) and metformin combined with sulfonylurea (29.0%). Regarding co-medication, 76.9% of the patients used antihypertensive drugs whereas only 33.1% and 39.9% were on aspirin and statin therapy, respectively. ADA recommendations for annual eye and foot examination were not followed in 38.8% (eye) and 39.2% (feet) of the patients. Conclusion The current management of type 2 diabetic Flemish patients falls short of recommended treatment goals. Community pharmacists may play a role in enhancing the awareness of glycaemic control and in stimulating selfmanagement in diabetic patients by motivating patients towards correct medication use, better medication adherence, healthy lifestyle and smoking cessation.


Type 2 diabetes Pharmacotherapy Self-management Community pharmacists Belgium 



We wish to thank the students and supervising pharmacists for their efforts in conducting this survey, and all patients who kindly agreed to participate in the study and gave their permission to publish the results. Financially supported by Ghent University.


  1. 1.
    International Diabetes Federation. Diabetes Atlas Second Edition Executive Summary. Brussels: International Diabetes Federation; 2003. ISBN 2 930229 28 4. (accessed 2006 Oct 10).Google Scholar
  2. 2.
    World Health Organization. Prevention of diabetes mellitus. Technical report series no. 844. Geneva: World Health Organization; 1994. ISBN 92 4 120844 9.Google Scholar
  3. 3.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006;29:S4–42.Google Scholar
  4. 4.
    Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533–43.PubMedGoogle Scholar
  5. 5.
    Cranor CW, Bunting BA, Christensen DB. The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173–84.CrossRefGoogle Scholar
  6. 6.
    Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238–43.PubMedGoogle Scholar
  7. 7.
    Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Krass I, Taylor SJ, Smith C, Armour CL. Impact on medication use and adherence of Australian pharmacists’ diabetes care services. J Am Pharm Assoc 2005;45:33–40.CrossRefGoogle Scholar
  9. 9.
    Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc 2004;44:455–66.CrossRefGoogle Scholar
  10. 10.
    Clifford RM, Batty KT, Davis TM, et al. A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract 2002;10:85–9.Google Scholar
  11. 11.
    Baran RW, Crumlish K, Patterson H, et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counselling. Am J Health Syst Pharm 1999;56:1535–9.PubMedGoogle Scholar
  12. 12.
    Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002;45:S23–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Rothenbacher D, Rüter G, Saam S, Brenner H. Younger patients with type 2 diabetes need better glycaemic control: results of a community-based study describing factors associated with a higher HbA1c value. Br J Gen Pract 2003;53:389–91.PubMedGoogle Scholar
  15. 15.
    Monnier L, Grimaldi A, Charbonnel B, et al. Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory. Diabetes Metab 2004;30:35–42.PubMedCrossRefGoogle Scholar
  16. 16.
    Browne DL, Avery L, Turner BC, Kerr D, Cavan DA. What do patients with diabetes know about their tablets? Diabet Med 2000;17:528–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev 2005;18:CD005060.Google Scholar
  18. 18.
    de Weerdt I, Visser A, van der Veen E. Attitude behavior theories and diabetes education programmes. Patient Educ Counsel 1989;14:3–19.CrossRefGoogle Scholar
  19. 19.
    Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001;24:561–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycaemic control. Diabetes Care 2002;25:1159–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Gary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ 2003;29:488–501.PubMedGoogle Scholar
  22. 22.
    Ellis SE, Speroff T, Dittus RS, Brown A, Pichert JW, Elasy TA. Diabetes patient education: a meta-analysis and meta-regression. Patient Educ Couns 2004;52:97–105.PubMedCrossRefGoogle Scholar
  23. 23.
    Warsi A, Wang PS, LaValley MP, Avorn J, Solomon DH. Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med 2004;164:1641–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Mensing C, Boucher J, Cypress M, et al. National standards for diabetes self-management education. Diabetes Care 2006;29:S78–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Bayingana K, Demarest S, Gisle L, et al. Gezondheidsenquête België 2004. Wetenschappelijk Instituut Volksgezondheid, Brussels, Belgium, 2006 (IPH/EPI Reports nr 2006–035). (accessed 2006 Oct 10).Google Scholar
  27. 27.
    Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999;22:1887–98.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Els Mehuys
    • 1
    Email author
  • Leen De Bolle
    • 1
  • Luc Van Bortel
    • 2
  • Lieven Annemans
    • 3
  • Inge Van Tongelen
    • 1
  • Jean-Paul Remon
    • 1
  • Mimi Giri
    • 4
  1. 1.Pharmaceutical Care Unit, Faculty of Pharmaceutical SciencesGhent UniversityGentBelgium
  2. 2.Heymans Institute of Pharmacology, Faculty of Medicine and Health SciencesGhent UniversityGhentBelgium
  3. 3.Department of Public Health, Faculty of Medicine and Health SciencesGhent UniversityGhentBelgium
  4. 4.Department of Endocrinology and DiabetologyGhent University HospitalGhentBelgium

Personalised recommendations